[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"low-risk\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:low-risk":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,69,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618338","cares--customized-aftercare-report-for-evaluated-skin-cancer-patients-100618338",false,"NCT07330323","CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients","Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.","CARES","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Low-risk skin cancer patients:\n\n  1. Negative personal history for melanoma\n  2. Less than 100 naevi\n  3. Less than 5 clinically atypical naevi\n  4. Maximum 1 BCC in history\n  5. Maximum 1 SCC, and at least 5 years ago\n  6. AK: treated and controlled with clinical response\n  7. M Bowen: treated and controlled with clinical response\n* Adult subjects (between 18 years of age and 80 years) at time of enrolment\n\nExclusion Criteria:\n\n* Presence of dermatological lesions requiring immediate treatment at the time of consultation.\n* History of solid organ transplantation (Organ Transplant Recipient, OTR).\n* Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).\n* Failure to meet one or more of the inclusion criteria.\n* Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.","ALL","18 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits.\n\nThis project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts .\n\nThe personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.",[28,29,30],"Management","Low Risk","Skin Cancer",[32,33,34],"Skin cancer risk and management","personalized discharge letter","low-risk skin cancer patients","RECRUITING","2026-05-20",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":36,"type":39},{"date":42,"type":22},"2029-06",{"name":44,"class":45},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":46},"100603764","radiofrequency-ablation-for-management-of-benignindeterminate-thyroid-nodules-and-low-risk-papillary-thyroid-cancers-100603764","NCT07140757","Radiofrequency Ablation for Management of Benign\u002FIndeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers","Eligibility Criteria\n\n1. Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC\n2. Participant is over 18 years and is either not a surgical candidate or has declined surgery.\n3. Capable and willing to provide written informed consent\n4. Participant has one of the following diagnoses:\n\n   * Biopsy-proven benign thyroid nodules causing compressive and\u002For cosmetic symptoms who are requesting treatment,\n   * Biopsy-proven indeterminate nodules (AUS or follicular neoplasm)\n   * Papillary thyroid carcinoma (PTC) without metastasis\n   * Locally recurrent thyroid cancer (\\\u003C 2 cm).\n\nExclusion Criteria\n\n1. Participants meeting any of the following criteria will be excluded:\n2. Participants considered unsuitable for RFA by the treating physician",{"count":54,"type":22},50,"OBSERVATIONAL","To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.",[29,58,59],"Papillary Thyroid Cancer","Radiofrequency Ablation","2026-03-10",{"date":62,"type":39},"2026-03-11",{"date":64,"type":39},"2025-08-18",{"date":66,"type":22},"2030-12-31",{"name":68,"class":45},"M.D. Anderson Cancer Center",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100602408","shenbai-granules-for-preventing-recurrence-of-low-risk-colorectal-adenomas-100602408","NCT07123116","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas","Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas: A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\nTo be eligible for this study, all of the following inclusion criteria must be met:\n\n1. Aged 40-75 years, regardless of sex;\n2. Patients with histologically confirmed high-risk adenomas undergoing initial polypectomy, with high-quality colonoscopy performed within 14 days before randomization;\n3. Complete resection of all detected lesions during colonoscopy;\n4. Meeting TCM diagnostic criteria for spleen deficiency with dampness-heat syndrome;\n5. Provision of signed informed consent and ability to comply with long-term follow-up.\n\n   1. High-quality colonoscopy is defined as: Boston Bowel Preparation Scale (BBPS) score ≥6, cecal intubation with photo-documentation and withdrawal time ≥6 minutes. If quality standards cannot be confirmed, a repeat colonoscopy is required.\n\n      \\-\n\n      Exclusion Criteria:\n\n      Subjects who meet any of the following exclusion criteria will not be enrolled in this study:\n\n1\\) Complicated with malignant tumor or having a history of malignant tumor; 2) Personal or family history of familial polyposis or hereditary nonpolyposis colorectal cancer; 3) History of inflammatory bowel disease; 4) Suffering from malignant tumors of other systems except the study disease within 5 years before screening, except for malignant tumors that have been cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery); 5) Complicated with severe organic diseases such as cardiovascular and cerebrovascular diseases, autoimmune diseases, diseases of the motor, hematological, digestive, respiratory, immune, circulatory, reproductive, urinary, or endocrine systems, or patients with neuropsychiatric diseases, abnormal coagulation function, severe postoperative complications, such as gastrointestinal bleeding, perforation, cholangitis, abdominal infection, cardiopulmonary function depression, mesenteric laceration, or pneumoperitoneum, etc., or other acute and chronic diseases that may affect treatment and prognosis; those with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) levels exceeding 2.5 times the upper limit of normal, Alkaline Phosphatase (ALP) levels exceeding 2 times the upper limit of normal, or abnormal electrocardiogram results assessed by investigators as clinically significant; 6) Patients with active gastrointestinal diseases, at risk of gastrointestinal perforation, or suffering from other diseases that can significantly interfere with the absorption, distribution, metabolism, or excretion of the trial drug, such as inability to take oral drugs, uncontrolled nausea or vomiting, intestinal obstruction, chronic diarrhea due to extensive intestinal resection, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.; 7) Having used the following treatments that may have a preventive effect on colorectal adenomas within 3 months before screening, for 3 consecutive months, at least 2 times a week, with an interruption time of less than 2 weeks: taking non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen, celecoxib, etc, metformin, berberine hydrochloride, folic acid, vitamin D, selenium supplements, and calcium supplements, or maintaining systemic immunotherapy, or using Chinese patent medicines based on the indications in the instructions or Chinese herbal decoctions with the effects of invigorating spleen and replenishing qi, clearing heat and eliminating dampness; those who have undergone a washout period of 1 month or 5 half-lives of the drug whichever is longer can be enrolled; 8) Those with cold syndrome such as fear of cold, cold pain in the waist and abdomen, cold limbs, and preference for hot drinks when thirsty; 9) Pregnant or lactating women, as well as men or women of childbearing age who have plans for childbearing recently or within 7 months before the study; 10) Having participated in, or currently participating in, other clinical trials of drugs or research devices within 1 month before screening or within 5 half-lives of the trial drug whichever is longer, or planning to participate in any other clinical trials during this study; 11) Allergic constitution with a history of allergy to two or more drugs or foods or known allergy to the components of the study drug; 12) Other conditions deemed unsuitable for inclusion by the investigator, such as expected poor compliance, cognitive impairment, etc.\n\n\\-","40 Years","75 Years",{"count":79,"type":22},450,[25],"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas（LRCRA）.\n\nStudy Population: Post-resection patients with low-risk colorectal adenomas and Spleen Deficiency with Dampness-Heat Syndrome per TCM criteria.\n\nSample Size: 450 subjects (1:1 randomization; 225 per arm) accounting for ≤20% dropout.\n\nStudy Hypothesis (Exploratory) ： This exploratory trial aims to evaluate the potential efficacy and safety of Shenbai Granules, a TCM formula, in reducing LRCRA recurrence. Based on preliminary data suggesting a 32.64% relative risk reduction in LRCRA recurrence at 2 years, we hypothesize that Shenbai Granules may demonstrate clinically meaningful prevention of adenoma recurrence and offer a favorable safety profile in the target TCM syndrome population. No formal statistical hypothesis is tested.\n\nStatistical Analysis Analysis Sets: mITT (primary efficacy), PPS, SS (safety). Primary Analysis: Proportion difference (Newcombe method) and χ²\u002FFisher's exact test (stratified CMH if applicable).\n\nSensitivity analyses: PPS, tipping-point imputation for missing data. Safety: Descriptive summaries of AEs\u002FSAEs (MedDRA-coded), lab abnormalities.",[83,84,29],"Colorectal Adenoma","TCM","NOT_YET_RECRUITING","2025-08-08",{"date":88,"type":39},"2025-08-14",{"date":90,"type":22},"2025-08-15",{"date":92,"type":22},"2028-11-30",{"name":94,"class":95},"Jiangsu Famous Medical Technology Co., Ltd.","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100533534","phase-2-precise-neoadjuvant-chemoresection-of-low-grade-nmibc-100533534","NCT06227065","Precise Neoadjuvant Chemoresection of Low Grade NMIBC","Precise Neoadjuvant Chemoresection of Low Grade NMIBC Guided by Drug Screens in Patient Derived Organoidst: A Single Center, Open-label, Phase II Trial","POLO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed Informed Consent Form\n* ECOG performance status of 0 or 1\n* Previous history of low risk non-muscle invasive urothelial carcino-ma of the bladder with recurrent papillary tumor and negative urine cytology or Primary solitary papillary tumor, \\\u003C3cm and negative urine cytology\n\nExclusion Criteria:\n\n* Known previous high grade and\u002For intermediate or high risk non-muscle invasive bladder cancer\n* Anticoagulation other than acetylsalicylic acid\n* Previous Intravesical biological\u002Fimmuno- (BCG) therapy\n* Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol",{"count":105,"type":22},28,[107],"PHASE2","Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial. The investigators aim to use drug screens in PDOs to guide neoadjuvant intravesical instillation therapy with either Epirubicin, Mitomycin C, Gemcitabine or Docetaxel to achieve chemoresection NMIBC.",[110,111,112],"Bladder Cancer","Non-muscle Invasive Bladder Cancer","Low-risk",[114,115,116],"Patient derived organoids","Neoadjuvant chemoresection","Precise drug selection","2024-01-25",{"date":119,"type":39},"2024-01-26",{"date":121,"type":22},"2024-10",{"date":123,"type":22},"2029-10",{"name":125,"class":45},"University of Bern"]